Leadman(SZ:300289) Guo Ji Jin Rong Bao·2025-07-31 15:49Core Viewpoint - The company Lide Man is planning to acquire up to 70% of shares in Xiansheng Xiangrui, which will enhance its IVD business and overall competitiveness [1][4]. Group 1: Company Overview - Lide Man's stock price closed at 7.04 yuan with a total market value of 3.83 billion yuan as of July 31 [1]. - The company specializes in in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [5]. - Lide Man has experienced significant fluctuations in its financial performance, with revenues ranging from 3.7 billion yuan to 7.06 billion yuan from 2020 to 2024 [5]. Group 2: Target Company Overview - Xiansheng Xiangrui is engaged in the biopharmaceutical manufacturing sector, focusing on in vivo diagnostic reagents and human vaccines [2]. - The company was listed on the New Third Board in September 2022 and has been undergoing guidance for listing on the Beijing Stock Exchange since 2023 [3]. - Xiansheng Xiangrui's revenue from 2020 to 2024 shows a stable performance, with net profits ranging from 0.95 billion yuan to 1.49 billion yuan [3]. Group 3: Financial Implications of the Acquisition - The acquisition is expected to cost approximately 2.93 billion yuan for 70% of Xiansheng Xiangrui's shares based on its current market value [7]. - Lide Man's cash reserves were reported at 510 million yuan as of the first quarter of 2025, indicating a potential need for significant bank loans to finance the acquisition [7]. - The acquisition aims to improve Lide Man's financial situation, which has been characterized by alternating periods of profit and loss [6].